Company intelligence / Profile preview

AiViva BioPharma

Costa Mesa, California, United Statesaiviva.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Completed Phase 1/2 clinical trial of AIV001 for nonmelanoma skin cancer (December 2023). Initiated Phase 1 clinical trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema (May 2023). Received FDA clearance to administer AIV001 in facial skin by intradermal injection for nonmelanoma skin cancer (December 2024).

Therapeutic areas: OphthalmologyOncologyDermatology
Modalities: Small molecules (including axitinib/AIV001)
Industry: Biotech

Drug pipeline

2 assets

AIV007

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on AiViva BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AiViva BioPharma.

Explore the full profile